Pharma Focus on Weight-Loss Drugs Risks Insulin Supply, Experts Warn 2026

Pharmaceutical companies' increasing focus on GLP-1 weight-loss drugs could put insulin supply at risk, experts warn. The gold rush into blockbuster medications like Ozempic and Mounjaro may be diverting attention away from diabetes treatments such as insulin, according to the Access to Medicine Foundation.

The Netherlands-based non-profit group highlighted the issue in a recent report, noting that many people with diabetes still cannot access basic insulin, while the surging popularity of weight-loss jabs like Wegovy has shifted industry priorities.

Why the Pharma Industry Is Chasing Weight-Loss Drugs

GLP-1 medications such as Novo Nordisk's Ozempic and Eli Lilly's Mounjaro have revolutionized obesity and diabetes treatment. Since the launch of Wegovy in 2021, demand has exploded, driven by their effectiveness for weight loss.

Companies can charge far higher prices and enjoy greater profit margins on weight-loss injections and pills compared to traditional insulin. This financial incentive is steering research and development efforts toward obesity treatments, potentially at the expense of diabetes care.

The Overlooked Crisis: Insulin Access in Low- and Middle-Income Countries

Diabetes affects an estimated 589 million adults globally, with 81% living in low- and middle-income countries (LMICs) such as Pakistan, Egypt, and Jordan. In these regions, access to insulin remains a critical challenge.

Jay Iyer, chief executive of the Access to Medicine Foundation, emphasized that after 105 years of insulin development, many people with type 1 diabetes still do not have access to the drug. The focus on GLP-1s for obesity is not helping these patients.

While GLP-1 drugs are beginning to enter LMIC markets for obesity, the foundation warns that many countries are struggling to access these medications at all. The disparity in access highlights a broader issue of equitable healthcare.

What This Means for Patients with Diabetes

For people with type 1 diabetes, insulin is a lifeline. Any diversion of pharmaceutical resources away from insulin production and distribution could have dire consequences. Patients in LMICs are particularly vulnerable, as they already face significant barriers to obtaining essential medications.

The report underscores the need for a balanced approach that addresses both obesity and diabetes. While GLP-1 drugs offer promising treatments, they should not overshadow the fundamental need for insulin access.

Industry Response and Future Outlook

Pharmaceutical companies have not yet commented on the foundation's report. However, the growing scrutiny of GLP-1 drugs' impact on global health could prompt a reevaluation of priorities. The background to this story is set out in GLP-1 Drugs Not Working? Share Your Story and Find Alternatives. A related thread runs through Weight-Loss Drugs That Fail: Understanding GLP-1 Treatment Resistance.

Experts call for policies that ensure essential medicines like insulin remain accessible and affordable, even as innovation in weight-loss treatments accelerates. The challenge lies in aligning profit motives with public health needs. Earlier coverage in How GLP-1 Weight Loss Drugs Are Changing Relationships shows how the argument developed. A closer look at the same subject appears in GLP-1 Weight Loss Drugs: Impact on Relationships Revealed.

Key Takeaways

• Pharma's focus on GLP-1 weight-loss drugs may divert attention from insulin production.
• 589 million adults have diabetes, with 81% in low- and middle-income countries.
• Many patients still lack access to basic insulin, 105 years after its development.
• High profit margins on weight-loss drugs drive industry priorities.
• Experts urge balanced approach to address both obesity and diabetes.

Comparison of GLP-1 Drugs and Insulin

FAQ

The pharmaceutical industry's race to develop new cancer drugs is another example of how profit motives shape research priorities, sometimes at the expense of essential medicines. As we have seen with pharma firms race to orbit for new cancer drugs, the industry often pursues high-margin areas, raising questions about equitable access.

Similarly, infrastructure failures can put lives at risk, as highlighted by reports on drivers ignoring roadwork closures put lives at risk. In healthcare, neglecting essential supplies like insulin can have similarly dangerous consequences.

Public health advocates stress the importance of preparedness, whether for cardiac emergencies or medication shortages. The defibrillator gaps put 16 million at cardiac arrest risk is a reminder that gaps in essential health resources can have fatal outcomes.

Moreover, systemic issues in facilities, such as unsafe Texas ICE facility conditions put immigrants at risk, underscore the need for oversight and accountability in all sectors that impact health.